About Embla Medical

Sveinn Sölvason, President and CEO, comments:

“Sales in the first quarter of 2026 reached USD 232 million, representing reported growth of 15% and organic growth of 4%. We delivered strong performance in Prosthetics & Neuro Orthotics, driven by continued momentum and solid volume growth across regions and categories.

EBITDA margin was 17%, reflecting the impact of external factors such as FX and tariffs. We continue to execute with discipline and remain focused on delivering margin expansion as growth accelerates."

Embla will host a conference call on April 28, 2026 at 09:00 CET / 7:00 GMT / 3:00 EST.

Please visit our Investor Relations section for further information

We serve our investors, by communicating in an informative and honest way. We are ambitious about the way we interact. It is our policy to provide investors, analysts and other stakeholders with comprehensive and accurate information to improve the understanding of the current and expected development of Embla Medical.